DK1640009T3 - Östrogenforbindelser som antimitotiske midler - Google Patents

Östrogenforbindelser som antimitotiske midler

Info

Publication number: DK1640009T3
Authority: DK; Denmark
Prior art keywords: antimitotic agents; estrogen compounds; arthritis; estrogen; compounds
Prior art date: 1993-08-06

Application number

DK05016659T

Other languages

English (en)

Inventor

Amato Robert John D

Moses Judah Folkman

Original Assignee

Childrens Medical Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-06

Filing date

1994-08-02

Publication date

2009-01-26

1994-08-02 Application filed by Childrens Medical Center filed Critical Childrens Medical Center

2009-01-26 Application granted granted Critical

2009-01-26 Publication of DK1640009T3 publication Critical patent/DK1640009T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK05016659T 1993-08-06 1994-08-02 Östrogenforbindelser som antimitotiske midler DK1640009T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/102,767 US5504074A (en)	1993-08-06	1993-08-06	Estrogenic compounds as anti-angiogenic agents
PCT/US1994/008767 WO1995004535A1 (en)	1993-08-06	1994-08-02	Estrogenic compounds as anti-mitotic agents

Publications (1)

Publication Number	Publication Date
DK1640009T3 true DK1640009T3 (da)	2009-01-26

Family

ID=22291581

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK94924120T DK0713393T3 (da)	1993-08-06	1994-08-02	Östrogenforbindelser som anti-angiogenesemidler
DK05016659T DK1640009T3 (da)	1993-08-06	1994-08-02	Östrogenforbindelser som antimitotiske midler

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK94924120T DK0713393T3 (da)	1993-08-06	1994-08-02	Östrogenforbindelser som anti-angiogenesemidler

Country Status (12)

Country	Link
US (8)	US5504074A (da)
EP (3)	EP1927359A3 (da)
JP (3)	JPH09501433A (da)
AT (2)	ATE313327T1 (da)
AU (1)	AU7450994A (da)
CA (1)	CA2168850C (da)
DE (2)	DE69434584T2 (da)
DK (2)	DK0713393T3 (da)
ES (2)	ES2255704T3 (da)
HK (2)	HK1014504A1 (da)
PT (1)	PT1640009E (da)
WO (1)	WO1995004535A1 (da)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040214807A1 (en) *	1993-08-06	2004-10-28	D'amato Robert J.	Estrogenic compounds as anti-mitotic agents
US5504074A (en) *	1993-08-06	1996-04-02	Children's Medical Center Corporation	Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) *	1993-08-06	2005-06-21	The Children's Medical Center Corporation	Estrogenic compounds as anti-mitotic agents
EP0833641A4 (en) *	1995-06-07	2000-04-05	Merck & Co Inc	TREATMENT AND PREVENTION OF PROSTATE DISEASES
US6346510B1 (en) *	1995-10-23	2002-02-12	The Children's Medical Center Corporation	Therapeutic antiangiogenic endostatin compositions
US20030195180A1 (en) *	1995-12-12	2003-10-16	D'amato Robert John	Estrogenic compounds as anti-mitotic agents
DE69731473T2 (de)	1996-05-09	2005-10-27	Amrad Operations Pty. Ltd., Richmond	Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen
EP0930876B2 (en) *	1996-07-22	2010-07-07	Renovo Limited	Use of compounds that promote oestrogenic activity for acclerating the healing of skin wounds
US5958892A (en)	1996-07-30	1999-09-28	Board Of Regents, The University Of Texas System	2-methoxyestradiol-induced apoptosis in cancer cells
US5801012A (en)	1996-09-17	1998-09-01	Northwestern University	Methods and compositions for generating angiostatin
DE19654750A1 (de) *	1996-12-30	1998-07-02	Helmut Dr Med Zander	Verwendung von Wirkstoffen mit Östrogen-Wirkung zur Vorbeugung und Behandlung von Makuladegeneration
WO1998040077A1 (en) *	1997-03-11	1998-09-17	Allergan Sales, Inc.	Anti-angiogenic agents
IL132029A0 (en)	1997-03-26	2001-03-19	Biosource Tech Inc	Pharmaceutical compositions containing di-aryl ethers
US6207704B1 (en)	1997-06-09	2001-03-27	Massachusetts Institute Of Technology	Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
US20020002294A1 (en) *	1997-09-24	2002-01-03	D' Amato Robert J.	Estrogenic compounds as antiangiogenic agents
US6355630B1 (en)	1997-10-23	2002-03-12	American Home Products Corporation	Estra-1,3,5(10)-triene-7α-thioethers
US6689768B2 (en) *	1998-04-15	2004-02-10	Jenapharm Gmbh & Co. Kg	Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy
BR9911882A (pt)	1998-07-13	2005-02-15	Univ Texas	Processo de tratamento de câncer empregando anticorpos a aminofosfolipìdios
JP2002522380A (ja) *	1998-08-07	2002-07-23	アンドルシェルシュ・インコーポレイテッド	タイプ３３α−ヒドロキシステロイドデヒドロゲナーゼの阻害
EP1124545B1 (en)	1998-08-11	2004-12-15	EntreMed, Inc.	Use of 2-methoxyestradiol as anti-fungal agents
SI1107795T1 (en)	1998-09-04	2003-06-30	The Regents Of The University Of Michigan	Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
AU3579200A (en) *	1999-02-26	2000-09-14	Saltech I Goteborg Ab	Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
JP5317381B2 (ja) *	1999-08-23	2013-10-16	エントレメッドインコーポレイテッド	高純度２−メトキシエストラジオールの生成方法
US7087592B1 (en) *	1999-08-23	2006-08-08	Entre Med, Inc.	Compositions comprising purified 2-methoxyestradiol and methods of producing same
EP1955700B9 (en)	1999-09-30	2011-09-07	Harbor BioSciences, Inc.	Therapeutic treatment of androgen receptor driven conditions
AUPQ342599A0 (en) *	1999-10-14	1999-11-04	University Of Melbourne, The	Conjugates and uses thereof
US6696436B1 (en)	1999-10-26	2004-02-24	The United States Of America As Represented By The Department Of Health And Human Services	B-homoestra-1,3,5(10)-trienes as modulators of tubulin polymerization
US6518261B2 (en) *	2000-03-17	2003-02-11	Oncology Sciences Corporation	Use of eugenol in combination with other chemopreventative agents as prophylaxis for cancers
US7135581B2 (en)	2000-08-18	2006-11-14	Entremed, Inc.	Antiangiogenic agents
US6995278B2 (en) *	2000-08-18	2006-02-07	Entre Med, Inc.	Antiangiogenic agents
US20050192258A1 (en) *	2000-08-18	2005-09-01	Agoston Gregory E.	Antiangiogenic agents
JP2004537499A (ja) *	2000-11-27	2004-12-16	エントレメッドインコーポレイテッド	抗血管新生薬
US20050209310A1 (en) *	2000-12-22	2005-09-22	Chaplin David J	Methods for modulating tumor growth and metastasis
US7037906B1 (en) *	2000-12-22	2006-05-02	Oxigene, Inc.	Methods for modulating tumor growth and metastasis
US6632835B2 (en)	2001-02-22	2003-10-14	Nanodesign Inc.	Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
US6713081B2 (en) *	2001-03-15	2004-03-30	The United States Of America As Represented By The Department Of Health And Human Services	Ocular therapeutic agent delivery devices and methods for making and using such devices
US6593321B2 (en)	2001-06-11	2003-07-15	Southwest Foundation For Biomedical Research	2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
US20040229960A1 (en) *	2001-07-13	2004-11-18	David Sherris	Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003006002A1 (en) *	2001-07-13	2003-01-23	Oxigene, Inc.	Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US7488723B2 (en) *	2001-09-05	2009-02-10	Alcon, Inc.	Use of non-feminizing estrogens as treatment for retinal vascular diseases
US20030211075A1 (en) *	2001-09-27	2003-11-13	Thorpe Philip E.	Combined compositions for tumor vasculature coagulation and treatment
US20080279936A1 (en) *	2001-10-10	2008-11-13	The University Of Pittsburgh	Estradiol metabolites for reduction of endothelin production
US7023931B2 (en) *	2001-11-05	2006-04-04	Texas Instruments Incorporated	System and method for soft slicing
US7179798B2 (en) *	2001-11-16	2007-02-20	Russell R. Roby	Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
US20030187076A1 (en) *	2002-01-30	2003-10-02	Agoston Gregory E.	Non-steroidal analogs of 2-methoxyestradiol
WO2003073985A2 (en) *	2002-03-01	2003-09-12	Entremed, Inc.	New methods of using antiangiogenic agents
ES2449017T3 (es) *	2002-06-21	2014-03-17	The University Of Utah Research Foundation	Compuestos reticulados, y métodos de preparación y uso de los mismos
CA2491310C (en)	2002-07-15	2015-10-06	Board Of Regents, The University Of Texas System	Compositions comprising cell-impermeant duramycin derivatives
US7435419B2 (en) *	2002-07-19	2008-10-14	Beth Israel Deaconess Medical Center	Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en)	2002-07-19	2008-02-26	Beth Israel Deaconess Medical Center	Methods of treating pre-eclampsia or eclampsia
WO2005000198A2 (en) *	2003-05-07	2005-01-06	Cedars-Sinai Medical Center	An intracellular estradiol binding protein, a polynucleotide encoding the same and cell lines overexpressing the same
WO2005000402A2 (en)	2003-05-15	2005-01-06	University Of Utah Research Foundation	Anti-adhesion composites and methods os use thereof
AU2004275693A1 (en) *	2003-05-28	2005-04-07	Entremed, Inc.	Antiangiogenic agents
US20050032766A1 (en) *	2003-08-05	2005-02-10	Green Shawn J.	Use of estrogenic compounds as anti-fungal agents
US20050065136A1 (en) *	2003-08-13	2005-03-24	Roby Russell R.	Methods and compositions for the treatment of infertility using dilute hormone solutions
US20070224278A1 (en)	2003-11-12	2007-09-27	Lyons Robert T	Low immunogenicity corticosteroid compositions
US20050101582A1 (en)	2003-11-12	2005-05-12	Allergan, Inc.	Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) *	2003-11-12	2006-06-29	Allergan, Inc.	Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050250737A1 (en) *	2003-11-12	2005-11-10	Allergan, Inc.	Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
WO2005051357A1 (en) *	2003-11-19	2005-06-09	Entremed, Inc.	Antiangiogenic agents
AU2004297231B2 (en)	2003-12-04	2012-02-02	University Of Utah Research Foundation	Modified macromolecules and associated methods of synthesis and use
US20100330143A1 (en)	2003-12-04	2010-12-30	University Of Utah Research Foundation	Modified macromolecules and methods of making and using thereof
CN100548271C (zh)	2004-01-20	2009-10-14	阿勒根公司	用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物
CA2553690C (en)	2004-01-22	2016-05-24	Sung Lan Hsia	Topical co-enzyme q10 formulations and methods of use
US20070004689A1 (en) *	2004-03-12	2007-01-04	Agoston Gregory E	Antiangiogenic agents
JP2007529426A (ja) *	2004-03-12	2007-10-25	エントレメッドインコーポレイテッド	抗血管新生薬
US20050239758A1 (en) *	2004-04-21	2005-10-27	Roby Russell R	Hormone treatment of multiple sclerosis
US20050239757A1 (en) *	2004-04-21	2005-10-27	Roby Russell R	Hormone treatment of macular degeneration
US20070059336A1 (en) *	2004-04-30	2007-03-15	Allergan, Inc.	Anti-angiogenic sustained release intraocular implants and related methods
US8512738B2 (en)	2004-04-30	2013-08-20	Allergan, Inc.	Biodegradable intravitreal tyrosine kinase implants
US8425929B2 (en) *	2004-04-30	2013-04-23	Allergan, Inc.	Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244471A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244463A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Sustained release intraocular implants and methods for treating ocular vasculopathies
US7771742B2 (en)	2004-04-30	2010-08-10	Allergan, Inc.	Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US7993634B2 (en)	2004-04-30	2011-08-09	Allergan, Inc.	Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244465A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Drug delivery systems and methods for treatment of an eye
US7799336B2 (en)	2004-04-30	2010-09-21	Allergan, Inc.	Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en)	2004-04-30	2014-05-13	Allergan, Inc.	Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8455656B2 (en)	2004-04-30	2013-06-04	Allergan, Inc.	Kinase inhibitors
US20050244466A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Photodynamic therapy in conjunction with intraocular implants
US20050244458A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Sustained release intraocular implants and methods for treating ocular neuropathies
US8119154B2 (en) *	2004-04-30	2012-02-21	Allergan, Inc.	Sustained release intraocular implants and related methods
US8147865B2 (en) *	2004-04-30	2012-04-03	Allergan, Inc.	Steroid-containing sustained release intraocular implants and related methods
WO2005110374A1 (en) *	2004-04-30	2005-11-24	Allergan, Inc.	Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US8591885B2 (en) *	2004-04-30	2013-11-26	Allergan, Inc.	Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20050244478A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Anti-excititoxic sustained release intraocular implants and related methods
US20050244462A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Devices and methods for treating a mammalian eye
US8673341B2 (en) *	2004-04-30	2014-03-18	Allergan, Inc.	Intraocular pressure reduction with intracameral bimatoprost implants
US20050244461A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Controlled release drug delivery systems and methods for treatment of an eye
US9498457B2 (en)	2004-04-30	2016-11-22	Allergan, Inc.	Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8273383B2 (en) *	2004-05-04	2012-09-25	Children's Medical Center Corporation	Methods and compositions for treatment of preeclampsia
CA2573668A1 (en) *	2004-07-12	2006-02-16	Allergan, Inc.	Ophthalmic compositions and methods for treating ophthalmic conditions
US20060025390A1 (en) *	2004-07-28	2006-02-02	Roby Russell R	Treatment of hormone allergy and related symptoms and disorders
TW200611909A (en) *	2004-08-04	2006-04-16	Akzo Nobel Nv	Process for the preparation 2-substituted-derivatives of estrone and estradiol
TW200613316A (en) *	2004-08-26	2006-05-01	Akzo Nobel Nv	Process for the preparation of estrone and/or estradiol-derivates
JP5270161B2 (ja)	2004-09-24	2013-08-21	ベスイスラエルデアコネスメディカルセンター	妊娠合併症を診断および処置する方法
JP2008521822A (ja) *	2004-11-29	2008-06-26	エントレメッドインコーポレイテッド	抗血管形成剤を投与する方法、およびそれを用いて疾病を治療する方法
US20060148674A1 (en) *	2004-12-31	2006-07-06	Luduena Richard F	Therapeutic composition
US8168621B2 (en) *	2005-09-30	2012-05-01	Endece, Llc	6-substituted estradiol derivatives and methods of use
US20080119447A1 (en) *	2005-09-30	2008-05-22	James Yarger	6-alkoxyalkyl estradiol derivatives and methods of use
US10174070B2 (en)	2005-09-30	2019-01-08	Endece Llc	6-substituted estradiol derivatives and methods of use
US20070185069A1 (en) *	2005-11-14	2007-08-09	Plum Stacy M	Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US7627508B2 (en) *	2006-01-04	2009-12-01	S.R. Clarke, Inc.	Method for tracking employees
US20070176403A1 (en) *	2006-02-01	2007-08-02	Dennis Calderone	Air adjustable seat
US20070203227A1 (en) *	2006-02-24	2007-08-30	Herman Adlercreutz	Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors
JP2009530388A (ja) *	2006-03-20	2009-08-27	エントレメッドインコーポレイテッド	２−メトキシエストラジオールの疾患修飾性抗関節炎活性
US8747870B2 (en)	2006-04-20	2014-06-10	University Of Utah Research Foundation	Polymeric compositions and methods of making and using thereof
WO2007124132A2 (en) *	2006-04-20	2007-11-01	University Of Utah Research Foundation	Polymeric compositions and methods of making and using thereof
US20090286271A1 (en) *	2006-05-31	2009-11-19	Karumanchi Ananth S	Methods of Diagnosing and Treating Complications of Pregnancy
EP2038309A2 (en) *	2006-07-11	2009-03-25	University of Utah Research Foundation	Macromolecules modified with electrophilic groups and methods of making and using thereof
DK2099460T3 (da) *	2006-11-30	2017-01-02	Endece Llc	6-alkoxyalkylestradiolderivater og fremgangsmåder til anvendelse
US8969415B2 (en)	2006-12-01	2015-03-03	Allergan, Inc.	Intraocular drug delivery systems
US20080234243A1 (en) *	2007-01-31	2008-09-25	Lavallee Theresa M	Method of treating amyloidosis mediated diseases
US7911053B2 (en) *	2007-04-19	2011-03-22	Marvell World Trade Ltd.	Semiconductor packaging with internal wiring bus
WO2008137599A2 (en) *	2007-05-01	2008-11-13	Evestra, Inc.	2-alkoxyestradiol analogs and pharmaceutical preparations
KR20100102110A (ko)	2007-11-09	2010-09-20	페레그린 파마수티컬즈, 인크	항-ｖｅｇｆ 항체 조성물 및 방법
EP2633864A1 (en)	2008-07-25	2013-09-04	The Regents of the University of Colorado	Clip inhibitors and methods of modulating immune function
US7901904B2 (en) *	2008-10-16	2011-03-08	Naxospharma S.R.L.	Method and intermediates for preparing 2-alkoxy and 2-aryloxy estrogen compounds
WO2010132498A1 (en) *	2009-05-11	2010-11-18	Oxigene, Inc.	Vascular disrupting agents for treatment of polypoidal choroidal vasculopathy
ES2695931T3 (es)	2009-11-09	2019-01-11	Allergan Inc	Composiciones y métodos para estimular el crecimiento del pelo
DK2616477T3 (da)	2010-09-14	2017-02-20	Endece Llc	6-substitueret demethyl-estradiol-derivater som agonister af art ER-BETA
WO2012079088A2 (en)	2010-12-10	2012-06-14	The Johns Hopkins University	Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
US20120225849A1 (en) *	2011-03-01	2012-09-06	The University Of Kansas	2-Methoxyestradiol (2-ME2) Prodrug with Enhanced Bioavailability for Prophylaxis or Treatment of Cancerous or Non-Cancerous Condition
US10865383B2 (en)	2011-07-12	2020-12-15	Lineage Cell Therapeutics, Inc.	Methods and formulations for orthopedic cell therapy
US9353150B2 (en)	2012-12-04	2016-05-31	Massachusetts Institute Of Technology	Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN109602691A (zh)	2013-02-15	2019-04-12	阿勒根公司	持续药物递送植入物
WO2014144715A1 (en)	2013-03-15	2014-09-18	Memorial Sloan-Kettering Cancer Center	Hsp90-targeted cardiac imaging and therapy
ES2651442T3 (es) *	2014-12-30	2018-01-26	Curadis Gmbh	Esteroides C-19 para inhibir la neovascularización
US9907751B2 (en) *	2016-03-10	2018-03-06	RxOMEG Therapeutics LLC	Composition and method of use of colchicine oral liquid
WO2017197045A1 (en)	2016-05-11	2017-11-16	Movassaghi Mohammad	Convergent and enantioselective total synthesis of communesin analogs
EP3576726A1 (en)	2017-02-06	2019-12-11	Massachusetts Institute Of Technology	Methods and products related to glutaminase inhibitors
WO2018209239A1 (en)	2017-05-11	2018-11-15	Massachusetts Institute Of Technology	Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
US10226423B1 (en)	2017-12-20	2019-03-12	RxOMEG Therapeutics LLC	Colchicine drug-to-drug interactions
US11535634B2 (en)	2019-06-05	2022-12-27	Massachusetts Institute Of Technology	Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en)	2021-02-24	2024-07-09	Massachusetts Institute Of Technology	Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2584271A (en)	1948-06-19	1952-02-05	Searle & Co	Steroid derivatives and method for producing the same
GB857080A (en)	1956-05-29	1960-12-29	Syntex Sa	Cyclopentanophenanthrene derivatives and process for the production thereof
US3166577A (en)	1956-05-29	1965-01-19	Syntex Corp	1, 2-dimethyl estrogens and intermediates used in the production thereof
GB857081A (en)	1956-05-29	1960-12-29	Syntex Sa	Cyclopentanophenanthrene derivatives and process for the production thereof
US2846453A (en)	1957-05-28	1958-08-05	Searle & Co	Alpha-ring-acylated estrone derivatives, and corresponding alcohols, their esters, and ethers
JPS42928Y1 (da)	1964-07-25	1967-01-19
US3562260A (en)	1965-08-23	1971-02-09	Ormonoterapia Richter Spa	2-carbonyl-estratrienes and method of their preparation
US3470218A (en)	1966-12-27	1969-09-30	Allied Chem	New 2-substituted estrogenic steroids
US3410879A (en)	1967-04-12	1968-11-12	American Home Prod	Process for preparing gonahexaenes
US3492321A (en)	1968-01-22	1970-01-27	Syntex Corp	Cyclopropenyl estra, -1,3,5(10)-trienes
US3496272A (en)	1968-01-23	1970-02-17	American Home Prod	Ester of 3-(2-propynyloxy)-estradiol
US3487155A (en)	1968-02-19	1969-12-30	Sandoz Ag	Substituted estradiol alkyl ethers
DE2004516A1 (en)	1969-03-05	1970-09-10	VEB Jenapharm, Jena	Thermpentic steroidal sulphonate esters
US3950437A (en)	1972-12-25	1976-04-13	Oxirane Chemical Co.	Method for manufacture of dihydric phenols
GB1502635A (en)	1974-02-27	1978-03-01	Schering Ag	Process for splitting steroid ethers
JPS5265259A (en)	1975-11-27	1977-05-30	Takeda Chem Ind Ltd	Synthesis of 16beta-alkylestradiol or its 17-esters
NL7613248A (nl)	1976-11-26	1978-05-30	Akzo Nv	Werkwijze voor het bereiden van nieuwe steroid- esters.
US4172132A (en) *	1977-07-26	1979-10-23	Schering Corporation	1,3,5(10),6,8,14-19-Nor-pregnahexaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor
DE2757157C3 (de)	1977-12-19	1980-10-09	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Verfahren zur Herstellung von 16 a -alkylierten Steroiden
FR2515188A1 (fr) *	1981-10-27	1983-04-29	Roussel Uclaf	Nouveaux derives du 3-amino-pregn-5-ene, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
FI830078L (fi)	1982-01-15	1983-07-16	Lilly Co Eli	Askorbinsyraetrar och liknande foereningar
US4994443A (en)	1982-12-20	1991-02-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
US5001116A (en) *	1982-12-20	1991-03-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
US4552758A (en)	1983-12-20	1985-11-12	St. Jude Children's Research Hospital	Human use of avian-human reassortants as vaccines for influenza A virus
US4522758A (en) *	1983-12-22	1985-06-11	Eli Lilly And Company	Method of preparing 2-fluoro-17β-estradiol
US4634705A (en)	1984-06-06	1987-01-06	Abbott Laboratories	Adrenergic amidines
DE3583900D1 (de)	1984-06-06	1991-10-02	Abbott Lab	Adrenergische verbindungen.
SU1240038A1 (ru)	1984-11-23	1996-10-27	Уральский политехнический институт им.С.М.Кирова	3-оксиэстра-1,3,5-триен-17-гидразон, обладающий гормональной и противоопухолевой активностью
WO1987002367A2 (en)	1985-10-18	1987-04-23	The Upjohn Company	Cyclic hydrocarbons with an aminoalkyl sidechain
JPS62135472A (ja)	1985-12-10	1987-06-18	Yakult Honsha Co Ltd	新規な１，２−ビス−３，５−ジオキソピペラジニルエタン誘導体
US4743597A (en) *	1986-01-27	1988-05-10	Javitt Norman B	Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
JP2544136B2 (ja)	1986-05-23	1996-10-16	第一製薬株式会社	硫酸化多糖体ｄｓ４１５２を含有する血管新生抑制剤及び抗腫瘍剤
DE3625315A1 (de)	1986-07-25	1988-01-28	Schering Ag	11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
JP2517561B2 (ja)	1986-10-03	1996-07-24	新技術事業団	カテコ−ルエストロゲンのイムノアツセイキツド
US5352664A (en)	1986-10-31	1994-10-04	Board Of Regents, The University Of Texas System	Thrombin derived polypeptides; compositions and methods for use
DE3872234T2 (de)	1987-04-16	1993-01-07	Upjohn Co	Zyklische kohlenwasserstoffe mit aminoalkyl-seitenkette.
US4808402A (en)	1987-05-29	1989-02-28	Northwestern University	Method and compositions for modulating neovascularization
US5135919A (en)	1988-01-19	1992-08-04	Children's Medical Center Corporation	Method and a pharmaceutical composition for the inhibition of angiogenesis
JPH01240038A (ja)	1988-03-19	1989-09-25	Fujitsu Ltd	ピーク値比較型タイミング再生方式
EP0477195A1 (en)	1989-06-16	1992-04-01	The Upjohn Company	Suramin type compounds and angiostatic steroids to inhibit angiogenesis
US4990538A (en) *	1989-08-23	1991-02-05	Harris Adrian L	Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
JPH03240726A (ja)	1990-02-15	1991-10-28	Fujisawa Pharmaceut Co Ltd	化学療法効果増強剤
JPH0446120A (ja)	1990-06-11	1992-02-17	Kyowa Hakko Kogyo Co Ltd	血管新生抑制剤
IT1247827B (it)	1991-02-05	1995-01-02	Erba Carlo Spa	Benzoil carbinolo e suoi esteri, utili come inibitori dell'angiogenesi
WO1993003729A1 (en) *	1991-08-12	1993-03-04	Research Corporation Technologies, Inc.	N-substituted phenoxazines for treating multidrug resistant cancer cells
US6011024A (en)	1991-08-28	2000-01-04	Imperial College Of Science Technology & Medicine	Steroid sulphatase inhibitors
EP0614463B1 (en) *	1991-11-22	2003-02-12	Alcon Laboratories, Inc.	Angiostatic steroids
DE69233125T2 (de)	1991-12-02	2004-04-22	Millennium Pharmaceuticals, Inc., South San Francisco	Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor
GB9207437D0 (en)	1992-04-03	1992-05-20	Orion Yhtymae Oy	Topical administration of toremifene and its metabolites
DE4235657A1 (de)	1992-10-22	1994-06-23	Schering Ag	Verfahren zum Alkylieren von Östronderivaten
CA2153686A1 (en)	1993-01-11	1994-07-21	Michihiko Kuwano	Angiogenesis inhibitor and novel compound
WO1994027635A1 (en) *	1993-05-27	1994-12-08	Entremed, Inc.	Compositions and methods for treating cancer and hyperproliferative disorders
US5643900A (en) *	1993-07-02	1997-07-01	Fotsis; Theodore	Method for treatment of pathological conditions associated with angiogenesis and preparation therefor
US5716981A (en)	1993-07-19	1998-02-10	Angiogenesis Technologies, Inc.	Anti-angiogenic compositions and methods of use
US6908910B2 (en) *	1993-08-06	2005-06-21	The Children's Medical Center Corporation	Estrogenic compounds as anti-mitotic agents
US5504074A (en) *	1993-08-06	1996-04-02	Children's Medical Center Corporation	Estrogenic compounds as anti-angiogenic agents
US5837682A (en)	1996-03-08	1998-11-17	The Children's Medical Center Corporation	Angiostatin fragments and method of use
HUT76095A (en)	1994-04-26	1997-06-30	Childrens Medical Center	Angiostatin and method of use for inhibition of angiogenesis
US5639725A (en)	1994-04-26	1997-06-17	Children's Hospital Medical Center Corp.	Angiostatin protein
GB9418067D0 (en) *	1994-09-07	1994-10-26	Orion Yhtymae Oy	Triphenylethylenes for the prevention and treatment of osteoporosis
US5521168A (en)	1994-10-13	1996-05-28	Alcon Laboratories, Inc.	Estrogen metabolites for lowering intraocular pressure
US5861372A (en)	1996-02-22	1999-01-19	The Children's Medical Center Corporation	Aggregate angiostatin and method of use
US5854205A (en)	1995-10-23	1998-12-29	The Children's Medical Center Corporation	Therapeutic antiangiogenic compositions and methods
US5854221A (en)	1996-12-12	1998-12-29	The Children's Medical Center Corporation	Endothelial cell proliferation inhibitor and method of use
WO1997034876A1 (en)	1996-03-15	1997-09-25	Zeneca Limited	Cinnoline derivatives and use as medicine
DE69731473T2 (de)	1996-05-09	2005-10-27	Amrad Operations Pty. Ltd., Richmond	Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen
US5958892A (en)	1996-07-30	1999-09-28	Board Of Regents, The University Of Texas System	2-methoxyestradiol-induced apoptosis in cancer cells
US5763432A (en)	1997-01-29	1998-06-09	Sri International	Steriod inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of use
US6051726A (en)	1997-03-13	2000-04-18	Pharm-Eco Laboratories, Inc.	Synthesis of 2-alkoxyestradiols
US6136992A (en)	1997-03-13	2000-10-24	The United States Of America As Represented By The Department Of Health And Human Services	2-alkoxy estradiols and derivatives thereof
CA2208916A1 (en)	1997-07-03	1999-01-03	Hyal Pharmaceutical Corporation	Promotion of wound healing utilizing steroids having reduced deterioroussystemic side effects typical of glucocorticoids, mineralocorticoids andsex steroids
US6011023A (en)	1997-08-27	2000-01-04	Alcon Laboratories, Inc.	Angiostatic steroids
AU1289899A (en)	1997-10-31	1999-05-24	Arch Development Corporation	Methods and compositions for regulation of 5-alpha reductase activity
US6046186A (en)	1997-12-24	2000-04-04	Sri International	Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
US6054446A (en)	1997-12-24	2000-04-25	Sri International	Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
JPH11209322A (ja)	1998-01-27	1999-08-03	Kao Corp	イソバニリルアルコール誘導体
JP2002522380A (ja)	1998-08-07	2002-07-23	アンドルシェルシュ・インコーポレイテッド	タイプ３３α−ヒドロキシステロイドデヒドロゲナーゼの阻害
EP1124545B1 (en)	1998-08-11	2004-12-15	EntreMed, Inc.	Use of 2-methoxyestradiol as anti-fungal agents
AU5687199A (en)	1998-08-24	2000-03-14	Global Vascular Concepts, Inc.	Use of anti-angiogenic agents for inhibiting vessel wall injury
US6284789B1 (en)	1998-09-04	2001-09-04	The Research Foundation Of State University Of New York	Formation and composition of new optically active compounds
CA2348234A1 (en)	1998-10-29	2000-05-11	Chunjian Liu	Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
US6358940B1 (en)	1999-09-07	2002-03-19	Rutgers, The State University	Modified 2-Alkoxyestradiol derivatives with prolonged pharmacological activity

1993
- 1993-08-06 US US08/102,767 patent/US5504074A/en not_active Expired - Lifetime
1994
- 1994-08-02 JP JP7506502A patent/JPH09501433A/ja not_active Ceased
- 1994-08-02 WO PCT/US1994/008767 patent/WO1995004535A1/en active IP Right Grant
- 1994-08-02 AT AT94924120T patent/ATE313327T1/de not_active IP Right Cessation
- 1994-08-02 ES ES94924120T patent/ES2255704T3/es not_active Expired - Lifetime
- 1994-08-02 DE DE69434584T patent/DE69434584T2/de not_active Expired - Fee Related
- 1994-08-02 DE DE69435151T patent/DE69435151D1/de not_active Expired - Fee Related
- 1994-08-02 EP EP08002915A patent/EP1927359A3/en not_active Withdrawn
- 1994-08-02 EP EP05016659A patent/EP1640009B1/en not_active Expired - Lifetime
- 1994-08-02 CA CA002168850A patent/CA2168850C/en not_active Expired - Fee Related
- 1994-08-02 AU AU74509/94A patent/AU7450994A/en not_active Abandoned
- 1994-08-02 PT PT05016659T patent/PT1640009E/pt unknown
- 1994-08-02 AT AT05016659T patent/ATE411029T1/de not_active IP Right Cessation
- 1994-08-02 DK DK94924120T patent/DK0713393T3/da active
- 1994-08-02 EP EP94924120A patent/EP0713393B1/en not_active Expired - Lifetime
- 1994-08-02 ES ES05016659T patent/ES2315763T3/es not_active Expired - Lifetime
- 1994-08-02 DK DK05016659T patent/DK1640009T3/da active
1995
- 1995-12-12 US US08/571,265 patent/US5661143A/en not_active Expired - Lifetime
1997
- 1997-04-25 US US08/838,699 patent/US5892069A/en not_active Expired - Fee Related
1998
- 1998-12-28 HK HK98115897A patent/HK1014504A1/xx not_active IP Right Cessation
1999
- 1999-02-02 US US09/243,158 patent/US6528676B1/en not_active Expired - Fee Related
2001
- 2001-02-12 US US09/780,650 patent/US7109187B2/en not_active Expired - Fee Related
2002
- 2002-09-25 US US10/255,652 patent/US20030055029A1/en not_active Abandoned
- 2002-10-25 US US10/280,831 patent/US7012070B2/en not_active Expired - Fee Related
2006
- 2006-04-12 US US11/402,386 patent/US7291610B2/en not_active Expired - Fee Related
- 2006-09-19 HK HK06110396.3A patent/HK1089387A1/xx not_active IP Right Cessation
2008
- 2008-02-22 JP JP2008041711A patent/JP2008120840A/ja active Pending
- 2008-02-22 JP JP2008041709A patent/JP2008120839A/ja active Pending

Also Published As

Publication number	Publication date
DK0713393T3 (da)	2006-05-08
US7291610B2 (en)	2007-11-06
JP2008120840A (ja)	2008-05-29
US7109187B2 (en)	2006-09-19
US5504074A (en)	1996-04-02
ES2315763T3 (es)	2009-04-01
HK1089387A1 (en)	2006-12-01
US20030096800A1 (en)	2003-05-22
EP0713393B1 (en)	2005-12-21
EP1640009A1 (en)	2006-03-29
ATE313327T1 (de)	2006-01-15
EP0713393A1 (en)	1996-05-29
EP1640009B1 (en)	2008-10-15
ES2255704T3 (es)	2006-07-01
DE69435151D1 (de)	2008-11-27
ATE411029T1 (de)	2008-10-15
DE69434584D1 (de)	2006-01-26
US20030236408A1 (en)	2003-12-25
CA2168850A1 (en)	1995-02-16
PT1640009E (pt)	2008-12-22
US20060183727A1 (en)	2006-08-17
DE69434584T2 (de)	2006-07-13
HK1014504A1 (en)	1999-09-30
CA2168850C (en)	2007-01-02
EP0713393A4 (en)	2000-10-25
US20030055029A1 (en)	2003-03-20
JP2008120839A (ja)	2008-05-29
US5892069A (en)	1999-04-06
AU7450994A (en)	1995-02-28
US7012070B2 (en)	2006-03-14
US5661143A (en)	1997-08-26
EP1927359A2 (en)	2008-06-04
WO1995004535A1 (en)	1995-02-16
JPH09501433A (ja)	1997-02-10
US6528676B1 (en)	2003-03-04
EP1927359A3 (en)	2008-06-11

Publication	Publication Date	Title
DK1640009T3 (da)	2009-01-26	Östrogenforbindelser som antimitotiske midler
DK0386997T3 (da)	1997-04-14	Anvendelse af 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater i behandlingen af psykose, inflammation og som immunosuppressive midler
MX9102728A (es)	1992-06-01	Resina de mesofase solvatada y metodo para su formacion.
DE69106603D1 (de)	1995-02-23	Fluorhaltiges Copolymer und dieses enthaltende härtbare Zusammensetzung.
ITVI930163A1 (it)	1994-01-19	Metodo per la realizzazione di supporti elestici integrali, nonche' supporti con esso ottenuti
FR2713423B1 (fr)	1996-03-29	Codeur et décodeur différentiels pour la modulation MDP-8 codée en treillis par l'approche pragmatique.
KR950701162A (ko)	1995-02-20	카르테시안 멀티 캐리어 피드백(cartesian multicarrier feedback)
NO954767D0 (no)	1995-11-24	4-amino-17 delser som C17-20-lyase- og 5
ES1032722Y (es)	1996-11-01	Lavadoras con fuelle perfeccionado.
DE59105763D1 (de)	1995-07-27	Tetra-N-glylcidylverbindung und deren härtbaren Gemische.
DE69422126D1 (de)	2000-01-20	Flüssigkristallzusammensetzung, Flüssigkristallvorrichtung und diese verwendende Vorrichtung
EP0624627A3 (en)	1995-03-01	Radiation-curable organopolysiloxane composition.
AU121935S (en)	1994-11-07	Fully retractable captive screw
ITMI910380A1 (it)	1992-08-15	Composti steroidei attivi sul sistema cardiovascolare
SE9200762D0 (sv)	1992-03-12	New topical use
EP0654526A3 (en)	1996-03-27	Cloud point lowering composition.
FR2706003B1 (fr)	1996-03-01	Roulement pour températures élevées.
FR2676677B1 (fr)	1993-11-05	Support d'etau pivotant et orientable.
Denniston	1989	“Illuminations” for wind ensemble
Marchenkov	1994	Hegel, Schopenhauer, Hanslick, and Langer on the meaning of music
Hämeen-Anttila	1993	The Text of K. al-Iʿtiqāb
Rogers	1993	Mutation, mind and epistemology; an examination of the concept of territoriality in humans as an informational and evolutionary phenomenon.
Pepper	1992	The effects of goal specificity, goal difficulty and goal source on endurance performance
ES1023891Y (es)	1994-04-01	Dispositivo limitador de velocidad perfeccionado para ascensores y similares.
ITTO910167U1 (it)	1993-01-12	Sopporto per tastiere di viteoterminali e simili.